Search

Your search keyword '"Patuzzo, Roberto"' showing total 35 results
Start Over Author "Patuzzo, Roberto" Publication Year Range Last 3 years
35 results on '"Patuzzo, Roberto"'

1. The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)

Author

Tropea, Saveria, Del Fiore, Paolo, Maurichi, Andrea, Patuzzo, Roberto, Santinami, Mario, Ribero, Simone, Quaglino, Pietro, Caliendo, Virginia, Borgognoni, Lorenzo, Sestini, Serena, Giudice, Giuseppe, Nacchiero, Eleonora, Caracò, Corrado, Cordova, Adriana, Solari, Nicola, Piazzalunga, Dario, Tauceri, Francesca, Carcoforo, Paolo, Lombardo, Maurizio, Cavallari, Sara, and Mocellin, Simone

Published
2022
Full Text
View/download PDF

2. Association of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures

Author

Maurichi, Andrea, primary, Barretta, Francesco, additional, Patuzzo, Roberto, additional, Sala, Laura, additional, Miceli, Rosalba, additional, Gallino, Gianfranco, additional, Mattavelli, Ilaria, additional, Leva, Andrea, additional, Simonotti, Nicolò, additional, Taglione, Bianca, additional, Cossa, Mara, additional, Belotti, Alessia, additional, Valeri, Barbara, additional, Cortinovis, Umberto, additional, and Santinami, Mario, additional

Published
2023
Full Text
View/download PDF

3. Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study

Author

Mattavelli, Ilaria, primary, Patuzzo, Roberto, additional, Galeone, Carlotta, additional, Pelucchi, Claudio, additional, Gallino, Gianfranco, additional, Leva, Andrea, additional, Valeri, Barbara, additional, Santinami, Mario, additional, and Maurichi, Andrea, additional

Published
2023
Full Text
View/download PDF

4. Supplementary Table 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 4 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 3 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure Legend from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 5 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Author

Filipazzi, Paola, primary, Pilla, Lorenzo, primary, Mariani, Luigi, primary, Patuzzo, Roberto, primary, Castelli, Chiara, primary, Camisaschi, Chiara, primary, Maurichi, Andrea, primary, Cova, Agata, primary, Rigamonti, Gianluigi, primary, Giardino, Felicetta, primary, Di Florio, Annabella, primary, Asioli, Marco, primary, Frati, Paola, primary, Sovena, Gloria, primary, Squarcina, Paola, primary, Maio, Michele, primary, Danielli, Riccardo, primary, Chiarion-Sileni, Vanna, primary, Villa, Antonello, primary, Lombardo, Claudia, primary, Tragni, Gabrina, primary, Santinami, Mario, primary, Parmiani, Giorgio, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

13. Data from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 1 from Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-α Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors

Author

Di Pucchio, Tiziana, primary, Pilla, Lorenzo, primary, Capone, Imerio, primary, Ferrantini, Maria, primary, Montefiore, Enrica, primary, Urbani, Francesca, primary, Patuzzo, Roberto, primary, Pennacchioli, Elisabetta, primary, Santinami, Mario, primary, Cova, Agata, primary, Sovena, Gloria, primary, Arienti, Flavio, primary, Lombardo, Claudia, primary, Lombardi, Arianna, primary, Caporaso, Patrizia, primary, D'Atri, Stefania, primary, Marchetti, Paolo, primary, Bonmassar, Enzo, primary, Parmiani, Giorgio, primary, Belardelli, Filippo, primary, and Rivoltini, Licia, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 1 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 5 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 4 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 2 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 3 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Methods from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 3 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figures 1-10 from Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma

Author

Anichini, Andrea, primary, Molla, Alessandra, primary, Vegetti, Claudia, primary, Bersani, Ilaria, primary, Zappasodi, Roberta, primary, Arienti, Flavio, primary, Ravagnani, Fernando, primary, Maurichi, Andrea, primary, Patuzzo, Roberto, primary, Santinami, Mario, primary, Pircher, Hanspeter, primary, Di Nicola, Massimo, primary, and Mortarini, Roberta, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 2 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

26. Similar local recurrence and survival in patients with T1 radial growth phase melanoma on head and neck treated with 5 or 10 mm margins: A retrospective study

Author

Maurichi, Andrea, primary, Barretta, Francesco, additional, Patuzzo, Roberto, additional, Miceli, Rosalba, additional, Gallino, Gianfranco, additional, Mattavelli, Ilaria, additional, Leva, Andrea, additional, Harwood, Catherine, additional, Bergamaschi, Daniele, additional, Borg, Tiffanie‐Marie, additional, Shimonovitz‐Moore, Michal, additional, Spadola, Giuseppe, additional, Tolomio, Elena, additional, Barbieri, Consuelo, additional, Queirolo, Paola, additional, Manganoni, Ausilia Maria, additional, Pellacani, Giovanni, additional, Espeli, Vittoria, additional, Mangas, Cristina, additional, Leoni‐Parvex, Sandra, additional, Cossa, Mara, additional, Belotti, Alessia, additional, Valeri, Barbara, additional, Cortinovis, Umberto, additional, and Santinami, Mario, additional

Published
2023
Full Text
View/download PDF

27. European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma

Author

Campana, Luca G, Farronato, Sofia, Hodgetts, Jackie, Odili, Joy, Vecchiato, Antonella, Bracken, Alison, Baier, Susanne, Bechara, Falk G, Borgognoni, Lorenzo, Caracò, Corrado, Carvalhal, Sara, Covarelli, Piero, Clover, James, Eisendle, Klaus, Fantini, Fabrizio, Fierro, Maria Teresa, Farricha, Victor, Gregorelli, Chiara, Hafner, Jürg, Kunte, Christian, Gerlini, Gianni, Hessam, Schapoor, Mandalà, Mario, Piazzalunga, Dario, Quaglino, Pietro, Snoj, Marko, Ross, Alastair Mackenzie, Trigona, Béatrice, Moreno-Ramirez, David, Tauceri, Francesca, Peach, Howard, Rutkowski, Piotr, Muir, Tobian, de Terlizzi, Francesca, Patuzzo, Roberto, Mühlstädt, Michael, Dietrich, Karin-Almut, Mussack, Thomas, Matteucci, Paolo, Kis, Erika, Ascierto, Paolo, Sersa, Gregor, Valpione, Sara, and Stingeni, Luca

Published
2023

28. The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts

Author

Stanganelli, Ignazio, Spagnolo, Francesco, Argenziano, Giuseppe, Ascierto, Paolo A, Bassetto, Franco, Bossi, Paolo, Donato, Vittorio, Massi, Daniela, Massone, Cesare, Patuzzo, Roberto, Pellacani, Giovanni, Quaglino, Pietro, Queirolo, Paola, Zalaudek, Iris, Palmieri, Giuseppe, On Behalf Of Italian Melanoma Intergroup Imi, Null, Stanganelli, Ignazio, Spagnolo, Francesco, Argenziano, Giuseppe, Ascierto, Paolo A, Bassetto, Franco, Bossi, Paolo, Donato, Vittorio, Massi, Daniela, Massone, Cesare, Patuzzo, Roberto, Pellacani, Giovanni, Quaglino, Pietro, Queirolo, Paola, Zalaudek, Iri, Palmieri, Giuseppe, On Behalf Of Italian Melanoma Intergroup Imi, Null, Stanganelli, I., Spagnolo, F., Argenziano, G., Ascierto, P. A., Bassetto, F., Bossi, P., Donato, V., Massi, D., Massone, C., Patuzzo, R., Pellacani, G., Quaglino, P., Queirolo, P., Zalaudek, I., and Palmieri, G.

Subjects
recommendation, Cancer Research, skin cancer, cutaneous squamous cell carcinoma, immune checkpoint inhibitor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immune checkpoint inhibitor, Review, Guideline, Recommendation, keratinocyte carcinomas, immune checkpoint inhibitors, Oncology, Keratinocyte carcinoma, recommendations, anti-PD-1, cemiplimab, guidelines, immunotherapy, guideline, keratinocyte carcinoma, RC254-282
Abstract

Simple Summary Cutaneous squamous cell carcinoma is one of the most common forms of cancer. Although most cases are cured with surgical excision, a few tumors are associated with a high risk of local or distant relapse; therefore, it is relevant to identify high-risk lesions among all other low-risk CSCCs for the proper diagnostic and therapeutic management. Chemotherapy achieves mostly short-lived responses that do not lead to a curative effect and are associated with severe toxicities. Recently, PD-1 inhibitor cemiplimab was approved by the regulatory authorities for the treatment of advanced cutaneous squamous cell carcinoma; subsequently, the anti-PD-1 agent pembrolizumab received the approval by the FDA only in the same setting. Here, we provide a literature review and clinical recommendations by a panel of experts regarding the diagnosis, treatment, and follow-up of cutaneous squamous cell carcinoma. Abstract Cutaneous squamous cell carcinomas (CSCC) account for about 20% of all keratinocyte carcinomas, which are the most common form of cancer. Heterogeneity of treatments and low mortality are a challenge in obtaining accurate incidence data and consistent registration in cancer registries. Indeed, CSCC mostly presents as an indolent, low-risk lesion, with five-year cure rates greater than 90% after surgical excision, and only few tumors are associated with a high-risk of local or distant relapse; therefore, it is particularly relevant to identify high-risk lesions among all other low-risk CSCCs for the proper diagnostic and therapeutic management. Chemotherapy achieves mostly short-lived responses that do not lead to a curative effect and are associated with severe toxicities. Due to an etiopathogenesis largely relying on chronic UV radiation exposure, CSCC is among the tumors with the highest rate of somatic mutations, which are associated with increased response rates to immunotherapy. Thanks to such strong pre-clinical rationale, clinical trials led to the approval of anti-PD-1 cemiplimab by the FDA (Food and Drug Administration) and EMA (European Medicines Agency), and anti-PD-1 pembrolizumab by the FDA only. Here, we provide a literature review and clinical recommendations by a panel of experts regarding the diagnosis, treatment, and follow-up of CSCC.

Published
2022

29. The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.

Author

Patuzzo, Roberto, Mattavelli, Ilaria, Gallino, Gianfranco, Galeone, Carlotta, Valeri, Barbara, Mocellin, Simone, Del Fiore, Paolo, Ribero, Simone, Mandalà, Mario, Tauceri, Francesca, Lombardo, Maurizio, and Maurichi, Andrea

Subjects
*CUTANEOUS malignant melanoma, *PROPORTIONAL hazards models, *PROGNOSIS
Abstract

Background: This study aimed to improve the understanding of the prognostic value of tumor mitotic rate (TMR) in cutaneous melanoma and assessed its significance as a predictor for overall, melanoma‐specific, and recurrence‐free survival. Patients and Methods: This is a retrospective multicenter Italian cohort study of 13,016 patients diagnosed with and treated for invasive primary melanoma between 2005 and 2020 with median follow‐up of 5.5 years. The survival probability was assessed by Kaplan–Meier method, hazard ratios (HRs), and corresponding 95% confidence interval (CI) of all‐cause mortality and recurrence/death by multivariable Cox proportional hazards models. Results: Higher dermal mitoses number was associated with decreased overall survival. Among patients with TMR 0/mm2, 1/mm2, 2/mm2–3/mm2, 4/mm2–10/mm2, and >10/mm2, 5‐year overall survival (OS) was 97.3%, 93.6%, 88.3%, 73.0%, and 60.9%, respectively. In multivariate analyses, compared to TMR of 0/mm2, HRs for all‐cause mortality were 1.35 (95% CI, 1.08–1.68), 1.70 (95% CI, 1.40–2.07), 2.04 (95% CI, 1.67–2.49), and 2.39 (95% CI, 1.90–3.00) for 1 mitoses/mm2, 2 mitoses/mm2–3 mitoses/mm2, 4 mitoses/mm2–10 mitoses/mm2, and >10 mitoses/mm2, respectively. A similar increase in risks was observed in melanoma‐specific survival (MSS) and recurrence‐free survival (RFS). The HRs for MSS and RFS for the highest compared to the lowest TMR category were 3.01 (95% CI, 2.20–4.11) and 2.26 (95% CI, 1.88–2.73), respectively. Sentinel lymph‐node biopsy positivity was significantly associated with TMR increase even with adjustment for several potential confounders. Conclusions: A clear association was demonstrated between an increasing TMR and decreased OS, MSS, and RFS, suggesting a reconsideration of TMR prognostic role for future inclusion in the melanoma staging system. Plain Language Summary: The 8th American Joint Committee on Cancer for melanoma staging removed tumor mitotic rate (TMR) from the staging criteria for T1 melanomas, giving way to ulceration and tumor thickness as stronger prognostic predictors.However, it is still recommended that TMR should be assessed and recorded in all primary invasive melanomas.In a large retrospective multicenter study on primary invasive melanomas, we investigated the prognostic value of TMR to assess its significance as survival predictor.Our results showed a clear association between increasing TMR and decreased patients' survival, suggesting that TMR should be considered for inclusion in the melanoma staging system. Increasing tumor mitotic rate (TMR) is clearly associated with decreased overall, melanoma‐specific, and recurrence‐free survival. Our results suggest that the prognostic role of TMR should be reconsidered, and dermal mitotic rate should be assessed and recorded for all primary melanomas. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.

Author

Bossi, Paolo, primary, Alberti, Andrea, additional, Bergamini, Cristiana, additional, Resteghini, Carlo, additional, Locati, Laura Deborah, additional, Alfieri, Salvatore, additional, Cavalieri, Stefano, additional, Colombo, Elena, additional, Gurizzan, Cristina, additional, Lorini, Luigi, additional, Tovazzi, Valeria, additional, Zamparini, Manuel, additional, Ravanelli, Marco, additional, Ascierto, Paolo Antonio, additional, Rampinelli, Vittorio, additional, Grammatica, Alberto, additional, Patuzzo, Roberto, additional, Maurichi, Andrea, additional, and Licitra, Lisa F., additional

Published
2022
Full Text
View/download PDF

31. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.

Author

DI GUARDO, LORENZA, RANDON, GIOVANNI, CORTI, FRANCESCA, VALLACCHI, VIVIANA, RAIMONDI, ALESSANDRA, FUCÀ, GIOVANNI, BINI, MARTA, MAURICHI, ANDREA, PATUZZO, ROBERTO, GALLINO, GIANFRANCESCO, MATTAVELLI, ILARIA, RUGGERI, ROBERTA, ANGI, MARTINA, COSSA, MARA, VALERI, BARBARA, CIMMINIELLO, CAROLINA, SANTINAMI, MARIO, RIVOLTINI, LICIA, DE BRAUD, FILIPPO, and RODOLFO, MONICA

Subjects
THERAPEUTIC use of antineoplastic agents, GENETIC mutation, BIOPSY, CONFIDENCE intervals, MELANOMA, PROTEIN kinase inhibitors, RETROSPECTIVE studies, CANCER patients, TREATMENT effectiveness, DESCRIPTIVE statistics, TERMINATION of treatment, EXTRACELLULAR space, TUMOR markers, DRUG toxicity, NUCLEIC acids, BLOOD
Abstract

Background. Outcomes of patients with metastatic melanoma discontinuing BRAF-targeted therapy for cumulative toxicity after sustained response are unknown. Materials and Methods. This retrospective case series analysis conducted at a single Cancer Center in Italy included patients with BRAF mutated metastatic melanoma treated with a BRAF inhibitor as a single agent or in combination with aMEK inhibitor between June 1, 2011 and January 1, 2020 and interrupted treatment due to cumulative toxicity after achieving complete response (CR) or long-lasting partial response (PR; i.e. >12 months). Results. We included 24 patients with a median treatment duration of 59.4 months (95% confidence interval [CI], 55.4-63.4; range, 12-88). CR and PR were achieved in 71% and 29% of patients, respectively. At a median follow-up after treatment discontinuation of 37.8 months (95% CI, 33.7-41.9), the 12-month progression-free survival after discontinuation (dPFS) rate was 70.8% (95% CI 54.8-91.6) and 24-month dPFS rate was 58.3% (95% CI, 41.6-81.8). Baseline patient and tumor characteristics as well as treatment duration and best response did not significantly impact on dPFS. Patients with CR and negative circulating tumor DNA (ctDNA) at time of discontinuation had a significantly improved dPFS compared with patients with either radiological residual disease or ctDNA positivity (p = .007). No patient in CR with undetectable ctDNA experienced progression. Conclusion. The risk of progression is high even in patients with sustained sensitivity to BRAF/MEK inhibitors. Integration of liquid biopsy in clinical trials investigating the optimal management of patients with sustained sensitivity to BRAF/MEK inhibitors is warranted. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)

Author

Saveria, Tropea, Paolo, Del Fiore, Andrea, Maurichi, Roberto, Patuzzo, Mario, Santinami, Simone, Ribero, Pietro, Quaglino, Virginia, Caliendo, Lorenzo, Borgognoni, Serena, Sestini, Giuseppe, Giudice, Eleonora, Nacchiero, Corrado, Caracò, Adriana, Cordova, Nicola, Solari, Dario, Piazzalunga, Francesca, Tauceri, Paolo, Carcoforo, Maurizio, Lombardo, Sara, Cavallari, Simone, Mocellin, Carlo, Riberti, Tropea, Saveria, Del Fiore, Paolo, Maurichi, Andrea, Patuzzo, Roberto, Santinami, Mario, Ribero, Simone, Quaglino, Pietro, Caliendo, Virginia, Borgognoni, Lorenzo, Sestini, Serena, Giudice, Giuseppe, Nacchiero, Eleonora, Caracò, Corrado, Cordova, Adriana, Solari, Nicola, Piazzalunga, Dario, Tauceri, Francesca, Carcoforo, Paolo, Lombardo, Maurizio, Cavallari, Sara, and Mocellin, Simone

Subjects
Oncology, Male, Treatment of cutaneous melanoma, medicine.medical_specialty, Completion lymph node dissection, Skin Neoplasms, CLND, Melanoma, Metastatic melanoma in the sentinel nodes, Nomogram, Overall survival, Prognostic factors, Risk stratification, Tumor burden, Humans, Lymph Node Excision, Lymphatic Metastasis, Prognosis, Retrospective Studies, Sentinel Lymph Node Biopsy, Tumor Burden, Lymphadenopathy, Sentinel Lymph Node, Settore MED/19 - Chirurgia Plastica, Internal medicine, Biopsy, medicine, medicine.diagnostic_test, business.industry, Sentinel node, medicine.disease, business
Abstract

Background: The management of melanoma patients with metastatic sentinel nodes (SN) is evolving based on the results of trials questioning the impact of completion lymph node dissection (CLND) and demonstrating the efficacy of new adjuvant treatments. In this landscape, new prognostic tools for fine risk stratification are eagerly sought to optimize the therapeutic path of these patients. Methods: A retrospective cohort of 2,086 patients treated with CLND after a positive SN biopsy in thirteen Italian Melanoma Centers was reviewed. Overall survival (OS) was the outcome of interest; included independent variables were the following: age, gender, primary melanoma site, Breslow thickness, ulceration, sentinel node tumor burden (SNTB), number of positive SN, non-sentinel lymph nodes (NSN) status. Univariate and multivariate survival analyses were performed using the Cox proportional hazard regression model. Results: The 3-year, 5-year and 10-year OS rates were 79 %, 70% and 54%, respectively. At univariate analysis, all variables, except for primary melanoma body site, were found to be statistically significant prognostic factors. Multivariate Cox regression analysis indicated that older age (P< 0.0001), male gender (P= 0.04), increasing Breslow thickness (P

Published
2022

33. Local Recurrence and Survival in Patients With Melanoma >2 mm in Thickness at Difficult Sites Treated With 1-cm Versus 2-cm Margins.

Author

Maurichi A, Barretta F, Patuzzo R, Gallino G, Mattavelli I, Shimonovitz-Moore M, Nizri E, Matteucci M, Summo V, Cossa M, Valeri B, Cortinovis U, Miceli R, and Santinami M

Abstract

Background: Melanoma guidelines recommend surgical excision with 2-cm margins for melanomas >2 mm in thickness. However, this procedure may be problematic at critical anatomic sites. We aimed to compare the outcomes of wide (2 cm) versus narrow (1 cm) excision margins in patients with melanoma >2 mm in thickness near critical structures., Patients and Methods: We retrospectively examined 736 patients undergoing excision with wide versus narrow margins at the National Cancer Institute in Milan, Italy, between 2001 and 2015., Results: A total of 265 (36.0%) patients received a wide local excision-82 (30.9%) with linear repair and 183 (69.1%) with flap or graft reconstruction. A total of 471 (64.0%) patients received a narrow excision-320 (67.9%) with linear repair and 151 (32.1%) with flap or graft reconstruction (P<.001). The 10-year overall survival rate was 69.5% (95% CI, 63.3%-76.2%) in the wide group and 68.7% (95% CI, 63.8%-74.0%) in the narrow group (P=.462); 10-year crude cumulative incidence (CCI) of local recurrence was 5.4% (95% CI, 3.2%-9.2%) in the wide and 8.8% (95% CI, 6.4%-12.1%) in the narrow group (P=.150). Multivariable Fine-Gray modeling of the CCI of local recurrence showed that Breslow thickness (P=.010) was the only statistically significant parameter. Multivariable Cox models for overall survival showed that age (P<.001), Breslow thickness (P<.001), and sentinel lymph node status (P=.019) were statistically significant covariates. Excision margin was not a significant parameter affecting patients' outcome., Conclusions: Wide local excision with 1-cm margins for melanoma >2 mm in thickness was not associated with an increased risk of local recurrence and did not affect overall survival.

Published
2024
Full Text
View/download PDF

34. European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma.

Author

Campana LG, Farronato S, Hodgetts J, Odili J, Vecchiato A, Bracken A, Baier S, Bechara FG, Borgognoni L, Caracò C, Carvalhal S, Covarelli P, Clover J, Eisendle K, Fantini F, Fierro MT, Farricha V, Gregorelli C, Hafner J, Kunte C, Gerlini G, Hessam S, Mandalà M, Piazzalunga D, Quaglino P, Snoj M, Ross AM, Trigona B, Moreno-Ramirez D, Tauceri F, Peach H, Rutkowski P, Muir T, de Terlizzi F, Patuzzo R, Mühlstädt M, Dietrich KA, Mussack T, Matteucci P, Kis E, Ascierto P, Sersa G, and Valpione S

Subjects
Humans, Quality Indicators, Health Care, Consensus, Benchmarking, Delphi Technique, Electrochemotherapy, Melanoma
Abstract

Background: Skin metastases are an important co-morbidity in melanoma. Despite broad adoption, electrochemotherapy implementation is hindered by a lack of treatment indications, uncertainty regarding procedural aspects, and the absence of quality indicators. An expert consensus may harmonize the approach among centres and facilitate comparison with other therapies., Methods: An interdisciplinary panel was recruited for a three-round e-Delphi survey. A literature-based 113-item questionnaire was proposed to 160 professionals from 53 European centres. Participants rated each item for relevance and degree of agreement on a five-point Likert scale, and received anonymous controlled feedback to allow revision. The items that reached concordant agreement in two successive iterations were included in the final consensus list. In the third round, quality indicator benchmarks were defined using a real-time Delphi method., Results: The initial working group included 122 respondents, of whom 100 (82 per cent) completed the first round, thus qualifying for inclusion in the expert panel (49 surgeons, 29 dermatologists, 15 medical oncologists, three radiotherapists, two nurse specialists, two clinician scientists). The completion rate was 97 per cent (97 of 100) and 93 per cent (90 of 97) in the second and third rounds respectively. The final consensus list included 54 statements with benchmarks (treatment indications, (37); procedural aspects, (1); quality indicators, (16))., Conclusion: An expert panel achieved consensus on the use of electrochemotherapy in melanoma, with a core set of statements providing general direction to electrochemotherapy users to refine indications, align clinical practices, and promote quality assurance programmes and local audits. The residual controversial topics set future research priorities to improve patient care., (© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

35. The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts.

Author

Stanganelli I, Spagnolo F, Argenziano G, Ascierto PA, Bassetto F, Bossi P, Donato V, Massi D, Massone C, Patuzzo R, Pellacani G, Quaglino P, Queirolo P, Zalaudek I, Palmieri G, and On Behalf Of Italian Melanoma Intergroup Imi

Abstract

Cutaneous squamous cell carcinomas (CSCC) account for about 20% of all keratinocyte carcinomas, which are the most common form of cancer. Heterogeneity of treatments and low mortality are a challenge in obtaining accurate incidence data and consistent registration in cancer registries. Indeed, CSCC mostly presents as an indolent, low-risk lesion, with five-year cure rates greater than 90% after surgical excision, and only few tumors are associated with a high-risk of local or distant relapse; therefore, it is particularly relevant to identify high-risk lesions among all other low-risk CSCCs for the proper diagnostic and therapeutic management. Chemotherapy achieves mostly short-lived responses that do not lead to a curative effect and are associated with severe toxicities. Due to an etiopathogenesis largely relying on chronic UV radiation exposure, CSCC is among the tumors with the highest rate of somatic mutations, which are associated with increased response rates to immunotherapy. Thanks to such strong pre-clinical rationale, clinical trials led to the approval of anti-PD-1 cemiplimab by the FDA (Food and Drug Administration) and EMA (European Medicines Agency), and anti-PD-1 pembrolizumab by the FDA only. Here, we provide a literature review and clinical recommendations by a panel of experts regarding the diagnosis, treatment, and follow-up of CSCC.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results